patients

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosisInventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from…

1 day ago
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding RiskAnthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk

Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk

--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction of bleeding with abelacimab compared…

4 days ago
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα…

3 weeks ago
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patientsLaminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients

Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients

PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative cancer therapy based…

4 weeks ago
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary FibrosisPliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

March 03, 2025 09:27 ET  | Source: Pliant Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) --…

1 month ago
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

March 01, 2025 12:45 ET  | Source: Celldex Therapeutics, Inc. - Greatly improved patient quality of life and reduced disease…

1 month ago
Vantage Foundation Brings Hope and Support to Patients at National Burn Hospital, HanoiVantage Foundation Brings Hope and Support to Patients at National Burn Hospital, Hanoi

Vantage Foundation Brings Hope and Support to Patients at National Burn Hospital, Hanoi

HANOI, Vietnam, Feb. 24, 2025 /PRNewswire/ -- Vantage Foundation proudly announces its partnership with National Burn Hospital Le Huu Trac in Hanoi,…

1 month ago
REPEAT/MEDIA ADVISORY – Patients who have been extra-billed for surgeries in private for-profit clinics demand accountability in the Ontario election: Press conferences in towns across OntarioREPEAT/MEDIA ADVISORY – Patients who have been extra-billed for surgeries in private for-profit clinics demand accountability in the Ontario election: Press conferences in towns across Ontario

REPEAT/MEDIA ADVISORY – Patients who have been extra-billed for surgeries in private for-profit clinics demand accountability in the Ontario election: Press conferences in towns across Ontario

February 15, 2025 08:00 ET  | Source: Ontario Health Coalition TORONTO, OTTAWA, LONDON and WINDSOR, Ontario, Feb. 15, 2025 (GLOBE…

2 months ago
UPDATE: Coalition of Groups Representing Tens of Millions of Patients Calls for Protection of the Nations Vital Health InfrastructureUPDATE: Coalition of Groups Representing Tens of Millions of Patients Calls for Protection of the Nations Vital Health Infrastructure

UPDATE: Coalition of Groups Representing Tens of Millions of Patients Calls for Protection of the Nations Vital Health Infrastructure

February 14, 2025 19:15 ET  | Source:

2 months ago
Coalition of Groups Representing Tens of Millions of Patients Calls for Protection of the Nations Vital Health InfrastructureCoalition of Groups Representing Tens of Millions of Patients Calls for Protection of the Nations Vital Health Infrastructure

Coalition of Groups Representing Tens of Millions of Patients Calls for Protection of the Nations Vital Health Infrastructure

February 14, 2025 18:20 ET  | Source:

2 months ago
Show more Posts